Anbalcabtagene Autoleucel: First Approval.

Anbalcabtagene autoleucel (RIMQARTO®) is a CAR T therapy that includes CAR T cells with dual PD-1 and TIGIT downregulation to mitigate T cell exhaustion. It is being developed by Curocell Inc. for the treatment of diffuse large B-cell lymphoma, acute lymphoblastic leukaemia and autoimmune diseases, which received its first approval in April 2026 in South Korea. This article summarizes the milestones in the development of anbalcabtagene autoleucel leading to this first approval for the treatment of relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults following ≥ 2 lines of systemic therapy.